This kit uses double-antibody sandwich enzyme-linked immunosorbent assay to detect the residues of double-stranded RNA (dsRNA).
Storage
The kit should be stored at 2-8°C. Aavoid direct sunlight. The validity period is 12 months.
General Description
mRNA has gained significant worldwide attention as a novel active ingredient in vaccines and gene therapies. The increasing demand for mRNA molecules has compelled mRNA manufacturers to quickly scale up production capacity while maintaining high mRNA quality. In vitro transcription by T7 polymerase is the standard procedure to synthesize mRNA. However, this procedure may introduce double-stranded RNA (dsRNA) contaminants from random priming of abortive transcripts, turn-around transcription, and antisense transcription. dsRNA immune activation results in the up-regulation of various pro-inflammatory cytokines, and cell death, which can lead to patient morbidity. Therefore, to improve the quality of mRNA translation, and minimize adverse effects, it is critical to carefully monitor in vitro-transcribed (IVT) mRNA products and confirm the removal of dsRNA after purification.
Citations
Publication ()
Have you cited DEIA-BZ002 in a publication? Let us know and earn a reward for your research.
Background
In recent years, messenger ribonucleic acid (mRNA) has emerged as a very promising tool in the correction of genetic disorders, infectious diseases, and tumor therapy, and the epidemic of a novel coronavirus pneumonia has given further impetus to the development of mRNA. In parallel with the technological development, it has been found that double-stranded RNA (dsRNA) impurities formed during in vitro transcription (IVT) can trigger cellular immune responses, thus affecting the application of mRNAs. The understanding of mRNA itself and the by-products produced in IVT has not yet kept pace with the rapid development of mRNA production and IVT. Phage RNA polymerases, such as T7 RNA polymerase (T7 RNAP), despite exhibiting high fidelity in RNA synthesis, also have byproducts in them. Common non-target molecules include abortive sequences, short transcripts, and dsRNA. Double-stranded RNA is not a single molecule and has a diverse population of molecules of different sizes and annealing levels. Both short abortive RNA fragments and the 3' end of full-length RNA can initiate complementary RNA synthesis from primary transcripts, leading to dsRNA production.
Figure 1. Double-stranded RNA generation mechanisms during IVT (Source: Martínez J, et al. 2012)
The dsRNA molecule is not ideal for mRNA therapeutic applications due to its inherent immunogenicity, and the innate cellular response to dsRNA byproducts recognized by receptors such as TLR3 adversely affects the efficacy of mRNA therapy. In conclusion dsRNA activation of TLR3 initiates a complex series of cascade reactions involving TRIF and transcription factors thereby inducing immune genes transcription.
It is therefore widely accepted that the ideal dsRNA content in mRNA preparations should be kept below 0.5%, and people need to adopt a strategy of complementary purification to reach this goal. Among the standard purification methods, including LiCl, alcohol precipitation, size exclusion and ion exchange chromatography, as well as silica matrix-based purification methods are not effective in removing dsRNA impurities from IVT mRNAs. To date, the most effective method for eliminating dsRNA contamination is the use of ion-pair reversed-phase high-performance liquid chromatography (HPLC). On the other hand, monitoring dsRNA residues and confirming purification efficiency in a timely manner are also essential to minimize side effects.
Alternative Names
dsRNA ELISA kit
References
1. Martínez J, et al. Purification of linearized template plasmid DNA decreases double-stranded RNA formation during IVT reaction. Front Mol Biosci. 2023 Sep 29;10:1248511.
2.Baiersdörfer M, et al. A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA. Mol Ther Nucleic Acids. 2019 Apr 15;15:26-35.
Q: Please provide information about the length , composition and how is this material obtained of dsRNA standard
A: Using our transcription kit random template, N1-Me-Pseudo UTP modification to synthesize 500bp dsRNA. The purity is about 95%.
Q: There are two antibodies for coating and two for detection. Which antibodies are these?
A: We have an antibody screening platform, which screens out a pair of optimal antibodies from 100 anti-dsRNA antibodies.
Q: Do you have any data for the specificity of this kit towards saRNA?
A: Only specifically recognizes dsDNA. No interference from other forms of nucleic acids and IVT enzymes
Q: What are the recommended storage conditions for this material and how long is expected to be stable?
A: 1. The kit should be stored at 2-8°C. Avoid direct sunlight. The validity period is 12 months. 2. After the coating strip is unpacked and used, the remaining coating strip should be sealed, stored at 2-8°C, and used within the validity period. 3. After the other components of the kit are used, they should be put back to 2-8°C in time and used within the validity period. 4. This kit should be transported refrigerated. 5. Production date and expiration date: see the product packaging label.
Q: What is the size of the dsRNA calibrator?
A: 300 ng/mL, 100 μL
Q: I would like to inquire whether this kit is suitable for use in the context of post IVT (in Vitro Transcription) reactions.
A: Yes. Our standard (500bp dsRNA) is synthesized by IVT. Using NanoDrop to determine the concentration, HPLC to determine purity, and then diluting to the concentration required for the standard.
Q: Which antibodies clones are used (J2,K2,K1 or proprietary) ?
A: The antibodies used in the ELISA reagent kit are company-selected. The capture antibody F2 (mouse IgG2a monoclonal antibody) is used for coating the plate, and the detection antibody is M5 (purified mouse IgM monoclonal antibody).
Q: What is the size (in pb) of the dsRNA recognize?
A: > 40 bp
Q: What is the size (in pb) of the dsRNA Calibrator?
A: 500 bp
Customer Reviews
My Review for Double-stranded RNA (dsRNA, modified) ELISA kit
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
Purification of linearized template plasmid DNA decreases double-stranded RNA formation during IVT reaction
Front Mol Biosci
Authors: Martínez J, Lampaya V, Larraga A, Magallón H, Casabona D.
After the COVID-19 pandemic, messenger RNA (mRNA) has revolutionized traditional vaccine manufacturing. With the increasing number of RNA-based therapeutics, valuable new scientific insights into these molecules have emerged. One fascinating area of study is the formation of double-stranded RNA (dsRNA) during in vitro transcription (IVT) which is considered a significant impurity, as it has been identified as a major trigger in the cellular immune response pathway. Therefore, there is a growing importance placed to develop and optimize purification processes for the removal of this by-product. Traditionally, efforts have primarily focused on mRNA purification after IVT through chromatographic separations, with anion exchange and reverse phase chromatography emerging as effective tools for this purpose. However, to the best of our knowledge, the influence and significance of the quality of the linearized plasmid have not been thoroughly investigated. Plasmids production involves the growth of bacterial cultures, bacterial harvesting and lysis, and multiple filtration steps for plasmid DNA purification. The inherent complexity of these molecules, along with the multitude of purification steps involved in their processing, including the subsequent linearization and the less-developed purification techniques for linearized plasmids, often result in inconsistent batches with limited control over by-products such as dsRNA. This study aims to demonstrate how the purification process employed for linearized plasmids can impact the formation of dsRNA. Several techniques for the purification of linearized plasmids based on both, resin filtration and chromatographic separations, have been studied. As a result of that, we have optimized a chromatographic method for purifying linearized plasmids using monolithic columns with C4 chemistry (butyl chains located in the surface of the particles), which has proven successful for mRNAs of various sizes. This chromatographic separation facilitates the generation of homogeneous linearized plasmids, leading to mRNA batches with lower levels of dsRNA during subsequent IVT processes. This finding reveals that dsRNA formation is influenced not only by RNA polymerase and IVT conditions but also by the quality of the linearized template. The results suggest that plasmid impurities may contribute to the production of dsRNA by providing additional templates that can be transcribed into sequences that anneal with the mRNA molecules. This highlights the importance of considering the quality of plasmid purification in relation to dsRNA generation during transcription. Further investigation is needed to fully understand the mechanisms and implications of plasmid-derived dsRNA. This discovery could shift the focus in mRNA vaccine production, placing more emphasis on the purification of linearized plasmids and potentially saving, in some instances, a purification step for mRNA following IVT
A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA
Mol Ther Nucleic Acids
Authors: Baiersdörfer M, Boros G, Muramatsu H, Mahiny A, Vlatkovic I, Sahin U, Karikó K.
The increasing importance of in vitro-transcribed (IVT) mRNA for synthesizing the encoded therapeutic protein in vivo demands the manufacturing of pure mRNA products. The major contaminant in the IVT mRNA is double-stranded RNA (dsRNA), a transcriptional by-product that can be removed only by burdensome procedure requiring special instrumentation and generating hazardous waste. Here we present an alternative simple, fast, and cost-effective method involving only standard laboratory techniques. The purification of IVT mRNA is based on the selective binding of dsRNA to cellulose in an ethanol-containing buffer. We demonstrate that at least 90% of the dsRNA contaminants can be removed with a good, >65% recovery rate, regardless of the length, coding sequence, and nucleoside composition of the IVT mRNA. The procedure is scalable; purification of microgram or milligram amounts of IVT mRNA is achievable. Evaluating the impact of the mRNA purification in vivo in mice, increased translation could be measured for the administered transcripts, including the 1-methylpseudouridine-containing IVT mRNA, which no longer induced interferon (IFN)-α. The cellulose-based removal of dsRNA contaminants is an effective, reliable, and safe method to obtain highly pure IVT mRNA suitable for in vivo applications.